+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Preclinical CRO Market Size, Share & Trends Analysis Report by Service (Toxicology Testing, Bioanalysis & DMPK Studies), by End Use (Biopharmaceutical Companies, Government & Academic Institutes), and Segment Forecasts, 2022-2030

  • PDF Icon

    Report

  • 275 Pages
  • April 2022
  • Region: Global
  • Grand View Research
  • ID: 5450194
The global preclinical CRO market size is expected to reach USD 9.67 billion by 2030, expanding at a CAGR of 7.9%. The market is expected to show lucrative growth due to increasing R&D expenditure and rising outsourcing trends. The increasing volume of new drugs entering the preclinical phase is also anticipated to boost the market during the forecast period. However, the COVID-19 pandemic had temporarily affected the market owing to the shutdown of research sites due to the implementation of national lockdowns.



The market is undergoing a series of mergers and acquisitions, resulting in improvement in full-service capabilities and the international reach of larger companies. For instance, in 2019, WuXi AppTec acquired Pharmapace. On the other hand, mid-sized and smaller contract research organizations are focusing on niche sectors and are providing a personalized approach to their sponsors. Various companies are focusing on research and development of new drugs and therefore are outsourcing these activities to launch efficient CRO services in the market. This, in turn, provides a positive atmosphere for joint ventures among market participants owing to the preference of sponsors to maximize their benefits.

The COVID-19 pandemic is ever increasing since the disease was first identified in China in December 2019. Until March 9, 2022, more than 4500 million cases of COVID-19 were reported globally; this pandemic has fast-tracked the development of vaccines and drug testing. There are currently over 195 COVID-19 vaccine candidates in preclinical studies.

Preclinical CRO Market Report Highlights

  • The toxicology testing segment accounted for the largest share of more than 25.48% in 2021 due to its significance in Investigational New Drug (IND)-enabling studies.
  • The Patient Derived Organoid (PDO) Model segment held the largest share of 80.47% in 2021, owing to the high accuracy obtained by this model.
  • The government and academic institutes segment is anticipated to witness the fastest CAGR of 8.2% during the forecast period. This growth is credited to the rising government initiatives in the healthcare sector, especially in developing economies.
  • North America held the highest revenue share of the global market in 2021. Huge investments in healthcare R&D, coupled with well-developed healthcare infrastructure in the U.S., contributed to the market growth in North America. Asia Pacific is projected to expand with the fastest CAGR of 10.9% during the forecast period.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Preclinical CRO Market

What is the estimated value of the Global Preclinical CRO Market?

The Global Preclinical CRO Market was estimated to be valued at $5.3 Billion in 2022.

What is the growth rate of the Global Preclinical CRO Market?

The growth rate of the Global Preclinical CRO Market is 7.9%, with an estimated value of $9.7 Billion by 2030.

What is the forecasted size of the Global Preclinical CRO Market?

The Global Preclinical CRO Market is estimated to be worth $9.7 Billion by 2030.

Who are the key companies in the Global Preclinical CRO Market?

Key companies in the Global Preclinical CRO Market include Wuxi Apptec, Inc. (Wai), Labcorp, Eurofins Scientific Se, Medpace Holdings Inc., Charles River Laboratories International, Inc., Intertek Group plc (Igp), Sga Sa, Ppd (Thermo Fisher Scientific, Inc.) and Crown Bioscience.

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Regional Scope
1.1.2 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective-1
1.10.2 Objective-2
1.10.3 Objective-3
1.10.4 Objective-4
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Preclinical CRO Market: Variables, Trends, & Scope
3.1 Segment Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.4 Rising R&D offshoring
3.4.1.1 Rising outsourcing trend
3.4.1.2 Life sciences companies focusing on their core competencieS
3.4.2 Market Restraint Analysis
3.4.2.1 Monitoring issues and lack of standardization
3.5 Preclinical CRO Market Analysis Tools
3.5.1 Porter’s Five Forces Analysis
3.5.2 Industry Analysis Porter’s
3.5.2.1 Competitor rivalry (High)
3.5.2.2 Bargaining power of buyers(high)
3.5.2.3 Bargaining power of suppliers(Low)
3.5.2.4 Threat of substitutes (low)
3.5.2.5 Threat of new entrants (Low)
3.5.3 PESTEL Analysis
3.5.3.1 PESTLE Analysis
3.5.3.1.1 Political and LegaL
3.5.3.1.1.1 Strengths
3.5.3.1.1.2 Weaknesses
3.5.3.1.1.3 Opportunities
3.5.3.1.1.4 Threats
3.5.3.1.2 Economic
3.5.3.1.2.1 Strengths
3.5.3.1.2.2 Weaknesses
3.5.3.1.2.3 Opportunities
3.5.3.1.2.4 Threats
3.5.3.1.3 Social and Environmental
3.5.3.1.3.1 Strengths
3.5.3.1.3.2 Weaknesses
3.5.3.1.3.3 Opportunities
3.5.3.1.3.4 Threats
3.6 COVID-19 Impact Analysis
Chapter 4 Preclinical CRO Market: Service Segment Analysis
4.1 Definitions & Scope
4.2 Preclinical CRO: Market Service Share Analysis, 2021 & 2030
4.3 Bioanalysis and DMPK Studies
4.3.1 Bioanalysis and DMPK studies market, 2018-2030 (USD Million)
4.3.2 In-vitro ADME
4.3.2.1 In-vitro Adme Market, 2018-2030 (USD Million)
4.3.3 In-Vivo Pk
4.3.3.1 In-Vivo Pk Market, 2018-2030 (USD Million)
4.4 Toxicology Testing
4.4.1 Toxicology Testing Market, 2018-2030 (USD Million)
4.4.2 Glp
4.4.2.1 Glp Market, 2018-2030 (USD Million)
4.4.3 Non-Glp
4.4.3.1 Non-Glp Market, 2018-2030 (USD Million)
4.5 Compound Management
4.5.1 Compound Management Companies market, 2018-2030 (USD Million)
4.5.2 Process R&D
4.5.2.1 Process r&D Market, 2018-2030 (USD Million)
4.5.3 Custom Synthesis
4.5.3.1 Custom Synthesis Market, 2018-2030 (USD Million)
4.5.4 Others
4.5.4.1 Others Market, 2018-2030 (USD Million)
4.6 Chemistry
4.6.1 Chemistry Testing Market, 2018-2030 (USD Million)
4.6.2 Medicinal Chemistry
4.6.2.1 Medicinal Chemistry Market, 2018-2030 (USD Million)
4.6.3 Computation Chemistry
4.6.3.1 Computation Chemistry Market, 2018-2030 (USD Million)
4.7 Safety Pharmacology
4.7.1 Safety Pharmacology market, 2018-2030 (USD Million)
4.8 Others
4.8.1 Others market, 2018-2030 (USD Million)
Chapter 5 Preclinical CRO Market: Model Type Segment Analysis
5.1 Definition & Scope
5.2 Preclinical CRO: Market Model Type Share Analysis, 2021 & 2030
5.3 Patient Derived Organoid (PDOs) Models
5.3.1 Patient Derived Organoid (PDOs) Models market, 2018-2030 (USD Million)
5.4 Patient Derived Xenograft (PDX) Models
5.4.1 Patient Derived Xenograft (PDX) Models market, 2018-2030 (USD Million)
Chapter 6 Preclinical CRO Market: End-use Segment Analysis
6.1 Definitions & Scope
6.2 Preclinical CRO: Market End-use Share Analysis, 2021 & 2030
6.3 Biopharmaceutical Companies
6.3.1 Biopharmaceutical companies market, 2018-2030 (USD Million)
6.4 Government and Academic Institutes
6.4.1 Government and Academic Institutes market, 2018-2030 (USD Million)
6.5 Medical Device Companies
6.5.1 Medical Device Companies market, 2018-2030 (USD Million)
Chapter 7 Preclinical CRO Market: Regional Analysis
7.1 Preclinical CRO: Market Share Analysis, 2021 & 2030
7.2 North America
7.2.1 North America Preclinical CRO market, 2018-2030 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. Preclinical CRO market, 2018-2030 (USD Million)
7.2.3 Canada
7.2.3.1 Canada preclinical CRO market, 2018-2030 (USD Million)
7.3 Europe
7.3.1 Europe preclinical CRO market, 2018-2030 (USD Million)
7.3.2 UK
7.3.2.1 UK preclinical CRO market, 2018-2030 (USD Million)
7.3.3 Germany
7.3.3.1 Germany Preclinical CRO market, 2018-2030 (USD Million)
7.3.4 France
7.3.5 France preclinical CRO market, 2018-2030 (USD Million)
7.3.6 Italy
7.3.7 Italy preclinical CRO market, 2018-2030 (USD Million)
7.3.8 Spain
7.3.9 Spain preclinical CRO market, 2018-2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific Preclinical CRO Market, 2018-2030 (USD Million)
7.4.2 Japan
7.4.2.1 Japan Preclinical CRO Market, 2018-2030 (USD Million)
7.4.3 China
7.4.3.1 China Preclinical CRO Market, 2018-2030 (USD Million)
7.4.4 India
7.4.4.1 India Preclinical CRO Market, 2018-2030 (USD Million)
7.4.5 Australia
7.4.5.1 Australia Preclinical CRO Market, 2018-2030 (USD Million)
7.4.6 South Korea
7.4.6.1 South Korea Preclinical CRO Market, 2018-2030 (USD Million)
7.5 Latin America
7.5.1 Latin America Preclinical CRO Market, 2018-2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Preclinical CRO Market, 2018-2030 (USD Million)
7.5.3 Mexico
7.5.4 Mexico Preclinical CRO Market, 2018-2030 (USD Million)
7.5.5 Argentina
7.5.5.1 Argentina Preclinical CRO Market, 2018-2030 (USD Million)
7.6 MEA
7.6.1 MEA Preclinical CRO Market, 2018-2030 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Preclinical CRO market, 2018-2030 (USD Million)
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Preclinical CRO market, 2018-2030 (USD Million)
Chapter 8 Company Profiles
8.1 Company Profiles
8.1.1 WuXi AppTec, Inc. (WAI)
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Service benchmarking
8.1.1.4 Strategic initiatives
8.1.2 LABCORP
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Service benchmarking
8.1.2.4 Strategic initiatives
8.1.3 Eurofins scientific se
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Service benchmarking
8.1.3.4 Strategic initiatives
8.1.4 Medpace holdings inc.
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Service benchmarking
8.1.5 Charles River Laboratories International, Inc.
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Service benchmarking
8.1.5.4 Strategic initiatives
8.1.6 Intertek group plc (igp)
8.1.6.1 Company overview
8.1.6.2 Financial performance
8.1.6.3 Service benchmarking
8.1.6.4 Strategic initiatives
8.1.7 SGA SA
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Service benchmarking
8.1.7.4 Strategic initiatives
8.1.8 PPD (THERMO FISHER SCIENTIFIC, INC.)
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Service benchmarking
8.1.8.4 Strategic initiatives
8.1.9 PRA Health Sciences, INC. (ICON plc)
8.1.9.1 Company overview
8.1.9.2 Financial performance
8.1.9.3 Service benchmarking
8.1.9.4 Strategic Initiatives
8.1.10 CROwn bioscience
8.1.10.1 Company overview
8.1.10.2 Financial performance
8.1.10.3 Service benchmarking
8.1.10.4 Strategic initiatives

Companies Mentioned

  • Wuxi Apptec, Inc. (Wai)
  • Labcorp
  • Eurofins Scientific Se
  • Medpace Holdings Inc.
  • Charles River Laboratories International, Inc.
  • Intertek Group plc (Igp)
  • Sga Sa
  • Ppd (Thermo Fisher Scientific, Inc.)
  • Pra Health Sciences, Inc. (Icon plc)
  • Crown Bioscience

Methodology

Loading
LOADING...